Skye Bioscience inc (OTCQB:SKYE) CEO Punit Dhillon talks to Proactive about results from its preclinical study assessing the neuroprotective properties of its SBI-100 ophthalmic nanoemulsion, the treated group demonstrated a trend of retaining the greater function of the eye’s retinal ganglion cells versus vehicle control. RGCs are cells that process and transmit visual information to the brain. The San Diego-based company said that the study was conducted using an aggressive optic nerve crush model in rats to evaluate the neuroprotective potential of SBI-100.
Skye Bioscience reports potential neuroprotective benefit of SBI-100 in preclinical glaucoma model
